Next report date
Report period
Q1 2024
EPS estimate
2.74TWD
Revenue estimate
437.00 MTWD
10.0TWD
274.83 MTWD
1.84 BTWD
14.29 M
About SYNGEN BIOTECH CO LTD
Sector
Industry
CEO
Wei Jen Chen
Website
Headquarters
Tainan
Founded
1999
ISIN
TW0008279001
FIGI
BBG007H158Y3
Syngen Biotech Co., Ltd. engages in the manufacture and sale of microbial pharmaceutical and Biochemical Nutrition. It specializes in strain identification, micro-organism fermentation, recovery and purification. Its products include active pharmaceutical ingredients, nutritional ingredients, biology fermentation products, functional food and biology agriculture and aquaculture. The company was founded on April 28, 1999 and is headquartered in Tainan, Taiwan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 8279 is 154.0 TWD — it has decreased by 0.32% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange SYNGEN BIOTECH CO LTD stocks are traded under the ticker 8279.
SYNGEN BIOTECH CO LTD is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
8279 stock is 0.32% volatile and has beta coefficient of 0.20. Check out the list of the most volatile stocks — is SYNGEN BIOTECH CO LTD there?
8279 earnings for the last quarter are 2.59 TWD per share, whereas the estimation was 3.65 TWD resulting in a −29.04% surprise. The estimated earnings for the next quarter are 1.99 TWD per share. See more details about SYNGEN BIOTECH CO LTD earnings.
SYNGEN BIOTECH CO LTD revenue for the last quarter amounts to 471.00 M TWD despite the estimated figure of 591.00 M TWD. In the next quarter revenue is expected to reach 462.00 M TWD.
Yes, you can track SYNGEN BIOTECH CO LTD financials in yearly and quarterly reports right on TradingView.
8279 stock has risen by 0.65% compared to the previous week, the month change is a 2.53% fall, over the last year SYNGEN BIOTECH CO LTD has showed a 19.37% decrease.
8279 net income for the last quarter is 57.01 M TWD, while the quarter before that showed 70.16 M TWD of net income which accounts for −18.74% change. Track more SYNGEN BIOTECH CO LTD financial stats to get the full picture.
Today SYNGEN BIOTECH CO LTD has the market capitalization of 4.19 B, it has increased by 1.32% over the last week.
Yes, 8279 dividends are paid annually. The last dividend per share was 5.00 TWD. As of today, Dividend Yield (TTM)% is 3.24%. Tracking SYNGEN BIOTECH CO LTD dividends might help you take more informed decisions.
SYNGEN BIOTECH CO LTD dividend yield was 3.29% in 2023, and payout ratio reached 49.31%. The year before the numbers were 3.09% and 42.18% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 8279 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SYNGEN BIOTECH CO LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SYNGEN BIOTECH CO LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SYNGEN BIOTECH CO LTD stock shows the buy signal. See more of SYNGEN BIOTECH CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SYNGEN BIOTECH CO LTD EBITDA is 402.33 M TWD, and current EBITDA margin is 21.90%. See more stats in SYNGEN BIOTECH CO LTD financial statements.